Analysts Conflicted on These Healthcare Names: ACADIA Pharmaceuticals (ACAD), Qiagen (QGEN) and Alcon (ALC)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on ACADIA Pharmaceuticals (ACAD), Qiagen (QGEN) and Alcon (ALC).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ACADIA Pharmaceuticals (ACAD)
In a report released yesterday, Ritu Baral from TD Cowen maintained a Buy rating on ACADIA Pharmaceuticals, with a price target of $37.00. The company’s shares closed last Wednesday at $21.48.
According to TipRanks.com, Baral is a top 100 analyst with an average return of
Currently, the analyst consensus on ACADIA Pharmaceuticals is a Strong Buy with an average price target of $32.62.
See Insiders’ Hot Stocks on TipRanks >>
Qiagen (QGEN)
TD Cowen analyst Daniel Brennan maintained a Hold rating on Qiagen yesterday and set a price target of $40.00. The company’s shares closed last Wednesday at $34.44.
According to TipRanks.com, Brennan is a 5-star analyst with an average return of
Qiagen has an analyst consensus of Moderate Buy, with a price target consensus of $44.16, representing a 28.7% upside. In a report issued on April 21, TipRanks – xAI also downgraded the stock to Hold with a $45.00 price target.
Alcon (ALC)
Barclays analyst Matt Miksic reiterated a Hold rating on Alcon yesterday and set a price target of $90.00. The company’s shares closed last Wednesday at $65.41.
According to TipRanks.com, Miksic is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alcon with a $96.46 average price target, which is a 46.0% upside from current levels. In a report released yesterday, Stifel Nicolaus also maintained a Hold rating on the stock with a $70.00 price target.
Read More on ACAD:
